AI-powered pharmaceutical company Formation Bio has raised USD 372 million in a Series D funding round led by Andreessen Horowitz (a16z), with participation from investors including Sanofi, Sequoia, Angel Growth, FPV Ventures, and more.
The proceeds will be allocated to the company’s strategies of acquiring and in-licensing clinical-stage assets from other biotech and pharma companies and enhancing its AI capabilities within drug development and clinical trials.
Formation Bio, formerly TrialSpark, accelerates drug development through a proprietary platform based on modern data, LLMs, AI agents, and other technology. The company acquires clinical-stage drugs from pharmaceutical companies, universities, and biotech firms and leverages its AI platform to develop these assets into commercialization.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.